Stockscreener 앱 받기
29.00
4.89%
-1.49
전일 마감가:
$30.49
열려 있는:
$30.72
하루 거래량:
2.93M
Relative Volume:
0.93
시가총액:
$3.35B
수익:
-
순이익/손실:
$-237.39M
주가수익비율:
-13.69
EPS:
-2.1183
순현금흐름:
$-224.58M
1주 성능:
+1.97%
1개월 성능:
-5.51%
6개월 성능:
-29.73%
1년 성능:
-1.69%
1일 변동 폭
$28.75
$31.00
1주일 범위
$27.16
$34.38
52주 변동 폭
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
29.00 | 3.52B | 0 | -237.39M | -224.58M | -2.1183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX) - Seeking Alpha
Can Viking Therapeutics Inc. maintain its current growth rateFed Meeting & Short-Term Swing Trade Alerts - mfd.ru
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market - Benzinga
Viking Therapeutics (VKTX) Is Up 16.0% After Fast-Tracking VK2735 Into Phase III Trials – Has The Bull Case Changed? - Yahoo Finance
Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential - Seeking Alpha
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth - 富途牛牛
Viking Therapeutics Advances VK2735 Toward Phase 3 After FDA Feedback - AD HOC NEWS
What is HC Wainwright's Forecast for VKTX Q4 Earnings? - MarketBeat
Is Viking Therapeutics (VKTX) Pricing Reflecting Recent Drug Development Progress? - simplywall.st
Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch - Intellectia AI
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Pipeline Momentum Boosts Viking Therapeutics as Phase 3 Timeline Accelerates - AD HOC NEWS
Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress - Yahoo Finance
Viking Therapeutics stock rating reiterated at Buy by Laidlaw - Investing.com Nigeria
Viking Therapeutics Bets Big on Obesity Breakthroughs - TipRanks
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Gap UpTime to Buy? - MarketBeat
Viking Therapeutics pushes GLP-1/GIP obesity pill to phase 3 - TechTarget
Viking to push oral GLP-1/GIP drug into phase III obesity trial - bioworld.com
Viking Therapeutics Stock Soars: What's Driving The Momentum? - Benzinga
Stock Movers: Equinix, Crocs, Viking Therapeutics - Bloomberg.com
Viking Therapeutics stock price target lowered to $118 by Raymond James By Investing.com - Investing.com Canada
Viking Therapeutics stock rating reiterated at Buy by Laidlaw By Investing.com - Investing.com South Africa
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - marketscreener.com
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $99 - 富途牛牛
Viking Therapeutics (VKTX) Shares Rise on Promising Obesity Drug Updates - GuruFocus
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Viking Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates - Yahoo Finance
Viking Therapeutics stock price target lowered to $118 by Raymond James - Investing.com
Viking Therapeutics rises after Q4 updates (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics Advances Oral Obesity Drug Toward Final Clinical Trials - AD HOC NEWS
Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating - marketscreener.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Viking Therapeutics stock soars on plans for Phase 3 obesity drug trial - Investing.com
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus - Bez Kabli
Viking Therapeutics, Inc. (VKTX) shares surged 11.7% in pre-market trading after the company announced plans to advance its oral obesity treatment drug to late-stage trials. - Bitget
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens - MSN
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Viking Therapeutics plans to advance oral obesity drug to late-stage testing - whbl.com
Viking Therapeutics Q4 2025 Earnings Call Highlights - Intellectia AI
Viking Therapeutics (VKTX) Advances Obesity Pipeline Amidst Fina - GuruFocus
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Inc (VKTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs - GuruFocus
Viking (VKTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Viking Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Viking Therapeutics stock climbs after Q4 report: Details - MSN
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast By Investing.com - Investing.com Nigeria
Viking Therapeutics reports Q4 EPS ($1.38), consensus (90c) - TipRanks
Viking Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast - Investing.com
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
1.12%
0.87%
자본화:
|
볼륨(24시간):